ALaSCA: A novelin silicosimulation platform to untangle biological pathway mechanisms, with a case study in Type 1 Diabetes progression
Authors: Louw Carla , Truter Nina , Bergh Wikus , van den Heever Martine , Horn Shade , Oudrhiri Radouane , van Niekerk Dawie , Loos Ben , Singh Raminderpal 
Published: March 2023

Introduction

The analysis of signaling pathways is a cornerstone in clarifying the biological mechanisms involved in complex genetic disorders. These pathways have intricate topologies, and the existing methods that are used for the interpretation of these pathways, remain limited. We have therefore developed the Adaptable Large-Scale Causal Analysis (ALaSCA) computational platform, which uses causal analysis and counterfactual simulation techniques. ALaSCA offers the ability to simulate the outcome of a number of different hypotheses to gain insight into the complex dynamics of biological mechanisms prior to, or even without, wet lab experimentation. ALaSCA is offered as a proprietary Python library for bioinformaticians and data scientists to use in their life sciences workflows. Here we demonstrate the ability of ALaSCA to untangle the pivots and redundancies within biological pathways of various drivers of a specific phenotypic process. This is achieved by studying a major disease of global relevance, namely Type 1 Diabetes (T1D), and quantifying causal relationships between antioxidant proteins and T1D progression. ALaSCA is also benchmarked against standard associative analysis methods.

Methods

We use ourin silicosimulation platform, ALaSCA, to apply both a number of machine learning (ML) and data imputation techniques, and perform causal inference and counterfactual simulation. ALaSCA uses standard ML and causal analysis libraries as well as custom code developed for data imputation and counterfactual simulation. Counterfactual simulation is a method for simulating potential or hypothetical model outcomes in the field of causal analysis (Glymour, Pearl and Jewell, 2016). We apply ALaSCA to T1D by using proteomic data from Liuet al.(2018), as the patients were selected based on the presence of T1D susceptible HLA (human leukocyte antigen)-DR/DQ alleles through genotyping at birth and followed prospectively. The genetic cause of T1D in this cohort is therefore known and the mechanism and proteins through which it causes T1D are well-characterized. This biological mechanism was converted into a directed acyclic graph (DAG) for the subsequent causal analyses. The dataset was used to benchmark the causal inference and counterfactual simulation capabilities of ALaSCA.

Results and discussion

After data imputation of the Liu,et al.(2018) dataset, causal inference and counterfactual simulation were completed. The causal inference output of the HLA, antioxidant, and non-causal proteins showed that the HLA proteins had the overall strongest causal effects on T1D, with antioxidant proteins having the overall second largest causal effects on T1D. The non-causal proteins showed negligibly small effects on T1D in comparison with the HLA and antioxidant proteins. With counterfactual simulation we were able to replicate evidence for and gain understanding into the protective effect that antioxidant proteins, specifically Superoxide dismutase 1 (SOD1), have in T1D, a trend which is seen in literature. We were also able to replicate an unusual case from literature where antioxidant proteins, specifically Catalase, do not have a protective effect on T1D.

Conclusion

By analyzing the disease mechanism, with the inferred causal effects and counterfactual simulation, we identified the upstream HLA proteins, specifically the DR alpha chain and DR beta 4 chain proteins as causes of the protective effect of the antioxidant proteins on T1D. In contrast, through counterfactual simulation of the unusual case, in which the DR alpha chain and DR beta 4 chain proteins are not present in the model, we saw that the adverse effect which the antioxidant proteins have on T1D is due to the HLA protein, DQ beta 1 chain, and not the antioxidant proteins themselves. Future work would entail the application of the ALaSCA platform on various other diseases, and to integrate it into wet lab experimental design in a number of different biological study areas and topics.